Formulation Design and Evaluation of Olmesartan Mucoadhesive Buccal Tablets

Abstract

The present study mucoadhesive buccal tablets of Olmesartan can be used to bypass the extensive hepatic first-pass metabolism and improve the bioavailability. The mucoadhesive Buccal tablets of Olmesartan are a drug of choice in the treatment of high blood pressure, heart failure, and diabetic kidneys. The FTIR results revealed that there was no interaction between drugs and other excipients. All the post-compression parameter was within acceptable limits. The in vitro drug release was in the range of 85.35% to 99.65% after 8 hrs the very best regression integrity (r) the best fit role model for F1 to F8 used to be zero-order and for F9 it was Higuchi matrix.